Market Exclusive

Analyst Downgrades – FibroGen (NASDAQ:FGEN) Stock Gets Downgraded By Goldman Sachs Group, Inc. (The) from Buy to Neutral

Analyst Ratings For FibroGen (NASDAQ:FGEN)

Today, FibroGen (NASDAQ:FGEN) stock was downgraded by Goldman Sachs Group, Inc. (The) from Buy to Neutral.

There are 1 hold rating, 7 buy ratings on the stock.

The current consensus rating on FibroGen (NASDAQ:FGEN) is Buy (Score: 2.88) with a consensus target price of $45.00 per share, a potential 27.66% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For FibroGen (NASDAQ:FGEN)
FibroGen (NASDAQ:FGEN) has insider ownership of 14.90% and institutional ownership of 43.83%.

Recent Trading Activity for FibroGen (NASDAQ:FGEN)
Shares of FibroGen closed the previous trading session at 35.25 up +0.55 1.59% with 288,932 shares trading hands.

Exit mobile version